SCHEMBL9945362

SCHEMBL9945362

CC(C)C(=O)c1ccc2cc(-c3ccc(F)cc3)ccc2n1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 2/20 0.38
HSD17B14 Q9BPX1 2/20 0.38
TNIK Q9UKE5 1/20 0.38
LRRK2 Q5S007 1/20 0.38
DHODH Q02127 2/20 0.37
PGR P06401 1/20 0.37
PDE2A O00408 1/20 0.37
MAPT P10636 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
SCN9A Q15858 2/20 0.36
AAK1 Q2M2I8 1/20 0.36
CHEK2 O96017 1/20 0.36
ABL1 P00519 1/20 0.36
BACE1 P56817 1/20 0.36
HTR2C P28335 1/20 0.35
MCHR1 Q99705 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15294421 0.77 HSD17B14 (0.51) HSD17B14MAPTCYP1A2BACE1
SCHEMBL2723291 0.76 BACE1 (0.46) DHODHCYP1A2CYP2C9BACE1
SCHEMBL2723625 0.75 AKR1C3 (0.45) HSD17B14DHODHSCN9A
SCHEMBL2724070 0.74 SCN9A (0.47) GRM2SCN9AABL1
SCHEMBL9945355 0.72 AAK1 (0.45) TNIKLRRK2DHODHPGRSCN9A
SCHEMBL10136676 0.72 MGAM (0.61) MAPTCYP1A2
SCHEMBL5020256 0.71 GLP1R (0.37) MAPT
SCHEMBL6597008 0.70 HDAC2 (0.53) GRM2MAPTCYP1A2
SCHEMBL9945361 0.70 AKR1C3 (0.51) MAPTCYP1A2SCN9AABL1
SCHEMBL1293407 0.70 HSD17B1 (0.46) HSD17B14LRRK2MAPTCYP1A2SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651905-B1 METALLOENZYME INHIBITOR COMPOUNDS INNOCRIN PHARMACEUTICALS INC (US) 2017-07-19 EP disclosed
US-8669274-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2014-03-11 US disclosed
US-8669274-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2014-03-11 US disclosed
WO-2012082746-A2 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2012-06-21 WO disclosed
US-20120149729-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-20120149729-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149729-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO GRM2 918/4885HSD17B14 155/4885TNIK 1763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.